Detection of autoantibodies to livin and survivin in Sera from lung cancer patients.
Detection of autoantibodies to livin and survivin in Sera from lung cancer patients.
复制标题
DOI：
10.1016/j.lungcan.2004.11.002
复制
发表时间：
2005-05
期刊：
影响因子：
5.3
通讯作者：
A. Yagihashi;K. Asanuma;D. Kobayashi;N. Tsuji;Yasuharu Shijubo;S. Abe;Y. Hirohashi;T. Torigoe;N. Sato;N. Watanabe
中科院分区：
文献类型：
--
作者：
A. Yagihashi;K. Asanuma;D. Kobayashi;N. Tsuji;Yasuharu Shijubo;S. Abe;Y. Hirohashi;T. Torigoe;N. Sato;N. Watanabe
Survivin和livin在癌细胞和转化细胞中高表达，但在正常分化组织中很少或不表达。尽管已经检测到人类抗体对癌症相关抗原的反应，但尚未在肺癌患者中描述对 Livin 的反应。我们使用重组蛋白通过特定的酶联免疫吸附测定 (ELISA) 检查了此类患者中抗 Livin 抗体的流行情况。使用确定为平均吸光度 +2S.D 的阳性截断值。对于健康对照样本，37 名肺癌患者中有 19 名（51.3%）抗 Livin 抗体呈阳性。在来自同一肺癌患者的 31 份样本中，18 份（58.1%）抗生存素抗体呈阳性。通过抗生存素和抗活素 ELISA 同时评估 31 名肺癌患者的血清。 21 名患者 (71%) 的生存素、生活素或两者均呈阳性。抗生存素抗体反应的强度与抗生存素反应的强度不相关。因此，与抗生存素抗体一样，可以在许多肺癌患者中检测到抗生存素抗体。同时测试这两种抗体可能有助于检测肺癌，但需要更广泛的研究来确定抗 Livin 抗体的临床意义。
Survivin and livin are highly expressed in cancer cells and transformed cells, but show little or no expression in normal differentiated tissues. Although human antibody responses to cancer-associated antigens have been detected, the response to livin has not yet been described in lung cancer patients. We examined prevalence of anti-livin antibodies in such patients with a specific enzyme-linked immunosorbent assay (ELISA) using recombinant protein. Using a cutoff value for positivity determined as the mean absorbance +2S.D. for healthy control samples, 19 of 37 lung cancer patients (51.3%) were positive for anti-livin antibodies. Of 31 samples from the same lung cancer patients, 18 (58.1%) were positive for anti-survivin antibodies. When sera from 31 lung cancer patients were assessed simultaneously by anti-survivin and anti-livin ELISAs. Twenty-one patients (71%) were positive for survivin, livin, or both. Intensity of anti-livin antibody responses did not correlate with intensity of anti-survivin responses. Like anti-survivin antibodies, anti-livin antibodies, thus, can be detected in many lung cancer patients. Testing for both antibodies together may prove useful in detecting lung cancer, but more extensive studies are needed to establish the clinical significance of anti-livin antibodies.